Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enVVeno Medical CorpNVNO · Entity 8104 | SVP & Chief Medical Officer | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enVVeno Medical Corp
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-11-30 | Direct | 0 |
Reported balance
After 2025-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-16 · Other · Disposed 100,000 · Balance 0 F1: The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units. |
| Common StockSEC Table I · non-derivative | Direct | 1,600 |
Reported balance
Holding disclosure · report date 2025-12-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,600 |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 18, 2025 17:47 UTC | enVVeno Medical Corp NVNO · Entity 8104 | OtherRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028392 · ownership.xml · derivative · entry 2 Glickman Marc H. · CIK 0001730171 · SVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 20:33 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 75,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001493152-24-051144 · ownership.xml · derivative · entry 1 Glickman Marc H. · CIK 0001730171 · SVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-12-18 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 18, 2024 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2027. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 17:05 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001493152-23-044057 · ownership.xml · derivative · entry 1 Glickman Marc H. · CIK 0001730171 · SVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-12-05 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:26 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 265,700 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001493152-21-030333 · ownership.xml · derivative · entry 2 Glickman Marc H. · CIK 0001730171 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,700 Underlying: Common Stock · 265,700 shares Expires 2031-11-30 F2 · derivative.exercise_date: The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:26 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-030333 · ownership.xml · nonDerivative · entry 1 Glickman Marc H. · CIK 0001730171 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,600 F1 · price: The Reporting Person was granted 100,000 restricted stock units on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve. Read SEC document |
| May 21, 2021 Filed May 25, 2021 17:15 UTC | enVVeno Medical Corp HJLI · Entity 8104 | PurchaseCommon Stock | 1,600 | $5.90 | $9,440.00 |
DisclosureSEC source: 0001493152-21-012878 · ownership.xml · nonDerivative · entry 1 Glickman Marc H. · CIK 0001730171 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · shares: On May 21, 2021, the reporting person purchased 1,600 shares of common stock on the open market at $5.90 per share. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:56 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 406,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004528 · ownership.xml · derivative · entry 1 Glickman Marc H. · CIK 0001730171 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,000 Underlying: Common Stock · 406,000 shares Expires 2031-02-18 F1 · security: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). F2 · derivative.exercise_date: The stock options vest in equal quarterly installments over a two a year period, however the stock options may only become exercisable following receipt by the registrant of stockholder approval to increase the size of the Plan sufficiently to permit the exercise in full of such stock options under the Plan. If the registrant's stockholders do not approve an increase in the size of the Plan, the options will be void. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 21:58 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 1,000,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001493152-20-013755 · ownership.xml · derivative · entry 1 Glickman Marc H. · CIK 0001730171 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 100,000 shares Expires 2030-07-18 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on July 18, 2020. The award is subject to time-based vesting and will vest in equal monthly portions over three years. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 17:44 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001493152-19-011362 · ownership.xml · derivative · entry 3 Glickman Marc H. · CIK 0001730171 · CMO and Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-07-26 F2 · derivative.exercise_date: The shares subject to the option shall vest quarterly over a three (3) year period commencing on July 26, 2019. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 17:44 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option (Right to Buy) · Derivative | 184,500 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001493152-19-011362 · ownership.xml · derivative · entry 2 Glickman Marc H. · CIK 0001730171 · CMO and Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,500 Underlying: Common Stock · 184,500 shares Expires 2026-10-01 F1 · price: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 1, 2016, and provides that the options will have vested over a period of 2 years, with 1/5th of the shares subject to the option vested on October 1, 2016, and with the remaining shares vesting in equal monthly installments over the 24 months thereafter. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 17:44 UTC | enVVeno Medical Corp HJLI · Entity 8104 | Disposition to issuerStock Option (Right to Buy) · Derivative | 184,500 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001493152-19-011362 · ownership.xml · derivative · entry 1 Glickman Marc H. · CIK 0001730171 · CMO and Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 184,500 shares Expires 2026-10-01 F1 · price: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 1, 2016, and provides that the options will have vested over a period of 2 years, with 1/5th of the shares subject to the option vested on October 1, 2016, and with the remaining shares vesting in equal monthly installments over the 24 months thereafter. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 1, 2016, and provides that the options will have vested over a period of 2 years, with 1/5th of the shares subject to the option vested on October 1, 2016, and with the remaining shares vesting in equal monthly installments over the 24 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.